Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Anixa Biosciences (ANIX – Research Report) and InMode (INMD – Research Report).
Anixa Biosciences (ANIX)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences today and set a price target of $12.00. The company’s shares closed last Tuesday at $4.42.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anixa Biosciences with a $12.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
InMode (INMD)
Needham analyst Michael Matson maintained a Hold rating on InMode today. The company’s shares closed last Tuesday at $24.50.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for InMode with a $32.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANIX:
- Anixa Biosciences begins dosing in second cohort of ovarian cancer CAR-T trial
- Anixa Biosciences granted ovarian cancer vaccine technology patent in Japan
- Meet Anixa Biosciences: Fly exclusive interview with CEO Amit Kumar
- Commercialization through large partner among Anixa goals, CEO tells The Fly
- Anixa could begin human testing for ovarian cancer vaccine by 2025, CEO says
